Clinic Roundup

• Circadian Technologies Ltd., of Melbourne, Australia, said the FDA approved the investigational new drug application filed by its wholly owned subsidiary, Vegenics Pty Ltd., to initiate clinical trials of VGX-100, a human antibody that acts against the human VEGF-C protein. The Phase I study will evaluate VGX-100 in a variety of late-stage cancers.